Goldline Pharmaceutical Financials

BSE: 544759

₹38.00

₹-1.16 (-2.96%)

As on 07-Sep-2026IST

Market cap

₹36 Cr

Revenue (TTM)

₹31 Cr

P/E Ratio

8.9

P/B Ratio

1.5

Div. Yield

0 %

Annual
Quarterly

Income Statement (₹ Cr)	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Operating Revenue	31.20	28.06	23.57	19.85	--	--
Total Income	31.20	28.06	23.57	19.85	--	--
Total Expenditure	24.12	22.00	19.26	17.64	--	--
EBITDA	7.08	6.06	4.30	2.21	--	--
Depreciation	0.24	0.25	0.16	0.18	--	--
EBIT	6.84	5.81	4.14	2.03	--	--
Interest	1.46	1.95	1.61	1.63	--	--
Other Income	0.00	--	--	0.00	--	--
Exceptional Items	--	--	--	--	--	--
Profit before Tax	5.39	3.86	2.53	0.40	--	--
Provision for Tax	1.27	1.02	0.72	0.14	--	--
Profit after Tax	4.12	2.83	1.81	0.26	--	--

Liabilities (₹ Cr)	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Shareholder's Funds	14.25	10.26	7.87	5.89	--	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	2.43	4.16	4.90	4.50	--	--
Current Liabilities	12.11	11.77	10.17	9.00	--	--
Total Liabilities	28.87	26.19	22.93	19.39	--	--

Assets (₹ Cr)	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Non-Current Assets	2.75	2.93	3.43	2.57	--	--
Current Assets	26.05	23.26	19.50	16.82	--	--
Total Assets	28.87	26.19	22.93	19.39	--	--
Total Debt*	9.16	11.03	11.13	10.83	--	--
Net Current Assets	13.93	11.49	9.33	7.83	--	--
Contingent Liabilities	3.37	0.77	--	--	--	--

Cashflow (₹ Cr)	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Cash From Operating Activities	2.81	3.18	2.92	2.39	--	--
Cash Flow from Investing Activities	-0.06	0.16	-1.11	-1.03	--	--
Cash from Financing Activities	-3.40	-2.89	-1.08	-1.44	--	--
Net Cash Inflow / Outflow	-0.65	0.45	0.74	-0.09	--	--

Financials Ratios	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Adjusted EPS (₹)	5.97	4.11	2.62	0.43	--	--
Cash EPS (₹)	6.32	4.47	2.86	0.72	--	--
Adjusted Book Value (₹)	18.03	12.25	8.78	6.81	--	--
Dividend per Share (₹)	--	--	--	--	--	--
Cash Flow per Share (₹)	4.08	4.61	12.71	11.96	--	--
Free Cash Flow per Share (₹)	1.67	1.52	-1.59	-3.24	--	--

Profitability Ratios	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
ROCE (%)	30.60	28.82	23.18	12.17	--	--
ROE (%)	39.41	39.06	35.62	6.28	--	--
ROA (%)	14.98	11.54	8.53	1.32	--	--
EBIT Margin (%)	21.92	20.69	17.57	10.25	--	--
Net Margin (%)	13.20	10.10	7.66	1.29	--	--
Cash Profit Margin (%)	13.97	10.99	8.36	2.18	--	--

Growth Ratios	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Revenue Growth (%)	11.20	19.05	18.73	--	--	--
EBIT Growth (%)	17.81	40.24	103.45	--	--	--
Net Profit Growth (%)	45.26	56.94	603.82	--	--	--
EPS Growth (%)	45.26	56.94	511.97	--	--	--
Book Value Growth (%)	47.19	39.53	48.37	--	--	--

Valuation Ratios	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Price / Earnings	--	--	--	--	--	--
Price / Book Value	--	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	2.44	3.06	3.36	6.60	--	--
Close Price (₹)	--	--	--	--	--	--
High Price (₹)	--	--	--	--	--	--
Low Price (₹)	--	--	--	--	--	--
Market Cap (₹ Cr)	--	--	--	--	--	--

Solvency Ratios	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Debt to Equity	0.64	1.08	1.42	1.84	--	--
Short term debt to equity ratio	0.42	0.55	0.73	0.84	--	--
Current Ratio	2.15	1.98	1.92	1.87	--	--
Quick Ratio	1.64	1.40	1.18	1.27	--	--
Interest Coverage	4.70	2.98	2.57	1.25	--	--

Operating Efficiency Ratios	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Debtors to sales (%)	51.70	38.11	40.83	43.47	--	--
Asset Turnover	1.13	1.14	1.11	1.02	--	--
Receivable days	156.90	132.15	141.33	158.65	--	--
Inventory Days	75.99	92.81	99.60	98.76	--	--
Payable days	64.86	64.28	79.87	57.32	--	--
Cash Conversion Cycle	168.03	160.68	161.06	200.09	--	--